Cargando…

Pulmonary manifestations of Sjögren's syndrome

In 9–20% of cases, Sjögren's syndrome is associated with various respiratory symptoms. The most typical manifestations are chronic interstitial lung disease (ILD) and tracheobronchial disease. The most common manifestation of ILD is nonspecific interstitial pneumonia in its fibrosing variant. O...

Descripción completa

Detalles Bibliográficos
Autores principales: Flament, Thomas, Bigot, Adrien, Chaigne, Benjamin, Henique, Helene, Diot, Elisabeth, Marchand-Adam, Sylvain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487244/
https://www.ncbi.nlm.nih.gov/pubmed/27246587
http://dx.doi.org/10.1183/16000617.0011-2016
_version_ 1784792449349058560
author Flament, Thomas
Bigot, Adrien
Chaigne, Benjamin
Henique, Helene
Diot, Elisabeth
Marchand-Adam, Sylvain
author_facet Flament, Thomas
Bigot, Adrien
Chaigne, Benjamin
Henique, Helene
Diot, Elisabeth
Marchand-Adam, Sylvain
author_sort Flament, Thomas
collection PubMed
description In 9–20% of cases, Sjögren's syndrome is associated with various respiratory symptoms. The most typical manifestations are chronic interstitial lung disease (ILD) and tracheobronchial disease. The most common manifestation of ILD is nonspecific interstitial pneumonia in its fibrosing variant. Other types of ILD, such as organising pneumonia, usual interstitial pneumonia and lymphocytic interstitial pneumonitis, are rare. Their radiological presentation is less distinctive, and definitive diagnosis may require the use of transbronchial or surgical lung biopsy. Corticosteroid therapy is the mainstay of ILD treatment in Sjögren's syndrome, but the use of other immunosuppressive drugs needs to be determined. ILD is a significant cause of death in Sjögren's syndrome. Tracheobronchial disease is common in Sjögren's syndrome, characterised by diffuse lymphocytic infiltration of the airway. It is sometimes responsible for a crippling chronic cough. It can also present in the form of bronchial hyperresponsiveness, bronchiectasis, bronchiolitis or recurrent respiratory infections. The management of these manifestations may require treatment for dryness and/or inflammation of the airways. Airway disease has little effect on respiratory function and is rarely the cause of death in Sjögren's syndrome patients. Rare respiratory complications such as amyloidosis, lymphoma or pulmonary hypertension should not be disregarded in Sjögren's syndrome patients.
format Online
Article
Text
id pubmed-9487244
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-94872442022-11-14 Pulmonary manifestations of Sjögren's syndrome Flament, Thomas Bigot, Adrien Chaigne, Benjamin Henique, Helene Diot, Elisabeth Marchand-Adam, Sylvain Eur Respir Rev European Respiratory Update In 9–20% of cases, Sjögren's syndrome is associated with various respiratory symptoms. The most typical manifestations are chronic interstitial lung disease (ILD) and tracheobronchial disease. The most common manifestation of ILD is nonspecific interstitial pneumonia in its fibrosing variant. Other types of ILD, such as organising pneumonia, usual interstitial pneumonia and lymphocytic interstitial pneumonitis, are rare. Their radiological presentation is less distinctive, and definitive diagnosis may require the use of transbronchial or surgical lung biopsy. Corticosteroid therapy is the mainstay of ILD treatment in Sjögren's syndrome, but the use of other immunosuppressive drugs needs to be determined. ILD is a significant cause of death in Sjögren's syndrome. Tracheobronchial disease is common in Sjögren's syndrome, characterised by diffuse lymphocytic infiltration of the airway. It is sometimes responsible for a crippling chronic cough. It can also present in the form of bronchial hyperresponsiveness, bronchiectasis, bronchiolitis or recurrent respiratory infections. The management of these manifestations may require treatment for dryness and/or inflammation of the airways. Airway disease has little effect on respiratory function and is rarely the cause of death in Sjögren's syndrome patients. Rare respiratory complications such as amyloidosis, lymphoma or pulmonary hypertension should not be disregarded in Sjögren's syndrome patients. European Respiratory Society 2016-06 /pmc/articles/PMC9487244/ /pubmed/27246587 http://dx.doi.org/10.1183/16000617.0011-2016 Text en Copyright ©ERS 2016. https://creativecommons.org/licenses/by-nc/4.0/ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
spellingShingle European Respiratory Update
Flament, Thomas
Bigot, Adrien
Chaigne, Benjamin
Henique, Helene
Diot, Elisabeth
Marchand-Adam, Sylvain
Pulmonary manifestations of Sjögren's syndrome
title Pulmonary manifestations of Sjögren's syndrome
title_full Pulmonary manifestations of Sjögren's syndrome
title_fullStr Pulmonary manifestations of Sjögren's syndrome
title_full_unstemmed Pulmonary manifestations of Sjögren's syndrome
title_short Pulmonary manifestations of Sjögren's syndrome
title_sort pulmonary manifestations of sjögren's syndrome
topic European Respiratory Update
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487244/
https://www.ncbi.nlm.nih.gov/pubmed/27246587
http://dx.doi.org/10.1183/16000617.0011-2016
work_keys_str_mv AT flamentthomas pulmonarymanifestationsofsjogrenssyndrome
AT bigotadrien pulmonarymanifestationsofsjogrenssyndrome
AT chaignebenjamin pulmonarymanifestationsofsjogrenssyndrome
AT heniquehelene pulmonarymanifestationsofsjogrenssyndrome
AT diotelisabeth pulmonarymanifestationsofsjogrenssyndrome
AT marchandadamsylvain pulmonarymanifestationsofsjogrenssyndrome